1195768-19-4

Basic information

• Product Name: Methyl 3-{[(2,6-difluoropheyl)sulfonyl]aMino}-2-fluorabenzoate
• Synonyms: Methyl 3-{[(2,6-difluoropheyl)sulfonyl]aMino}-2-fluorabenzoate;Methyl 3-{[(2,6-difluorophenyl)sulfonyl]aMino}-2-fluorobenzoate;Methyl 3-(2,6-difluorophenylsulfonaMido)-2-fluorobenzoate
• CAS NO: 1195768-19-4
• Molecular Formula: C₁₄H₁₀F₃NO₄S
• Molecular Weight: 345.2937096
• EINECS: -0
• Mol File: 1195768-19-4.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 445.4±55.0 °C(Predicted)
• Appearance: /
• Density: 1.507±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 6.68±0.10(Predicted)
• CAS DataBase Reference: Methyl 3-{[(2,6-difluoropheyl)sulfonyl]aMino}-2-fluorabenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-{[(2,6-difluoropheyl)sulfonyl]aMino}-2-fluorabenzoate(1195768-19-4)
• EPA Substance Registry System: Methyl 3-{[(2,6-difluoropheyl)sulfonyl]aMino}-2-fluorabenzoate(1195768-19-4)

Safety Data

• Hazardous Substances Data: 1195768-19-4(Hazardous Substances Data)

Usage

General Description

Methyl 3-{[(2,6-difluoropheyl)sulfonyl]aMino}-2-fluorabenzoate is a chemical compound with the molecular formula C15H13F3N2O4S. It belongs to the class of benzoic acid esters and contains a sulfonyl amino group. Methyl 3-{[(2,6-difluoropheyl)sulfonyl]aMino}-2-fluorabenzoate is commonly used in pharmaceutical and agrochemical research due to its potential biological activities. It is often employed as an intermediate in the synthesis of various drugs and pesticides. Additionally, its fluorinated structure makes it an interesting molecule for studying the effects of fluoro-substituted compounds in different applications. Due to its unique structure and potential medicinal properties, Methyl 3-{[(2,6-difluoropheyl)sulfonyl]aMino}-2-fluorabenzoate is a valuable chemical for further investigation and development in the field of medicinal and agrochemical chemistry.

Upstream product

• 437-86-5 2-fluoro-3-nitrotoluene 
• 317-46-4 2-fluoro-3-nitro-benzoic acid 
• 946126-94-9 2-fluoro-3-nitrobenzoic acid methyl ester 
• 161957-56-8 3-bromo-2-fluorobenzoic acid 
• 206551-41-9 2-fluoro-3-bromobenzoic acid methyl ester 
• 1042055-86-6 methyl 3-((tert-butoxycarbonyl)amino)-2-fluorobenzoate 
• 914223-43-1 3-amino-2-fluoro benzoic acid 
• 1195768-18-3 3-amino-2-fluorobenzoic acid methyl ester 
• 60230-36-6 2,6-difluorobenzene-1-sulfonyl chloride 

Downstream Products

• 1244644-50-5 C₃₁H₂₈F₃N₇O₃S₂ 
• 1195768-22-9 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1-methylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 
• 1195764-77-2 2,6-Difluoro-N-{2-fluoro-3-[2-(1-methylethyl)-5-(2-{[2-(methylsulfonyl)ethyl]amino}-4-pyrimidinyl)-1,3-thiazol-4-yl]phenyl}benzenesulfonamide 
• 1195769-46-0 N-{3-[2-(1,1-dimethylethyl)-5-(2-ethenyl-4-pyrimidinyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide 
• 1195767-33-9 N-[3-(2-(1,1-dimethylethyl)-5-{2-[2-(methylsulfonyl)ethyl]-4-pyrimidinyl}-1,3-thiazol-4-yl)-2-fluorophenyl]-2,6-difluorobenzenesulfonamide 
• 1195767-08-8 ethyl 3-{4-[4-(3-{[(2,6-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-2-(1,1-dimethylethyl)-1,3-thiazol-5-yl]-2-pyrimidinyl}propanoate 

Relevant articles and documents

C-TERMINAL SRC KINASE INHIBITORS

Provided herein are novel C-terminal Srk Kinase (CSK) inhibitors, e.g., having Formula G, I, II, or III. Also provided are methods of preparing the novel CSK inhibitors and method of using the novel CSK inhibitors for treating diseases or disorder such as cancer or for promoting immune response in a subject in need thereof. (G)

COMBINATION OF RIBOCICLIB AND DABRAFENIB FOR TREATING OR PREVENTING CANCER

The present disclosure relates to pharmaceutical combinations comprising a cyclin dependent kinase 4/6 (CDK4/6) inhibitor compound, (b) a B-Raf inhibitor compound, and optionally (c) an alpha-isoform specific phosphatidylinositol 3 -kinase (PI3K) inhibitor compound, for the treatment or prevention of cancer, as well as related pharmaceutical compositions, uses, and methods of treatment or prevention of cancer.

Thiazole kinase inhibitors

The invention belongs to the technical field of medicine, and particularly relates to a thiazole kinase inhibitor shown as a general formula (I), and pharmaceutically acceptable salts or stereisomers thereof, wherein R1, R2, R3, R4, m, n and p are defined